<DOC>
	<DOCNO>NCT00475566</DOCNO>
	<brief_summary>The purpose first-in-man study evaluate safety performance Dynalink®-E everolimus elute peripheral stent system treatment patient atherosclerotic de novo restenotic native superficial femoral proximal popliteal lesion . Abbott Vascular cease data analysis STRIDES Clinical Trial 2 year . The decision discontinue study relate safety concern . The rationale proposal base follow consideration : The performance DYNALINK-E STRIDES show device- procedure-related death stent fracture , rate additional revascularizations stable since approximately 14 month procedure . Evaluations bare metal nitinol DYNALINK ABSOLUTE stents clinical literature show low rate death , reintervention stent fracture , consistent STRIDES demonstrate safety nitinol stent platform DYNALINK-E . Long-term animal study show concern drug polymer coat DYNALINK-E - everolimus tissue concentration drop quantifiable limit approximately 17 month implant , vascular response coat normal widely patent lumen strut incorporated vessel tissue . The safety performance DYNALINK-E substantiate clinical pre-clinical data , clinical data similar product . Given demonstrate mechanical integrity stent along evidence healthy long-term vascular response , reasonable expectation continue low event rate .</brief_summary>
	<brief_title>A Safety Efficacy Study Dynalink®-E Everolimus Eluting Peripheral Stent System</brief_title>
	<detailed_description>A prospective , Non-Randomized , Single-arm , Multi-center , Clinical Study Evaluate Safety Performance Dynalink®-E , Everolimus Eluting Peripheral Stent System Treatment Atherosclerotic de Novo Restenotic Native Superficial Femoral Proximal Popliteal Artery Lesions .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Rutherford Becker Category 25 Single de novo restenotic lesion superficial femoral proximal popliteal artery Disease segment length 30170 mm &gt; 50 % diameter stenosis total occlusion Target reference vessel diameter 4.37.3 mm Target lesion previously treat stent surgery Rutherford Becker Category 0 , 1 , 6 Immunosuppressive disorder currently receive immunosuppressive agent Serum creatinine &gt; 2.5 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>